Grifols, (NASDAQ: GRFS) and Epirus Biopharmaceuticals (NASDAQ:EPRS) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, earnings, dividends and institutional ownership.

Institutional & Insider Ownership

21.9% of Grifols, shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Grifols, and Epirus Biopharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Grifols, $5.16 billion 5.61 $1.46 billion $0.90 23.54
Epirus Biopharmaceuticals N/A N/A N/A ($2.53) -0.06

Grifols, has higher revenue and earnings than Epirus Biopharmaceuticals. Epirus Biopharmaceuticals is trading at a lower price-to-earnings ratio than Grifols,, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Grifols, and Epirus Biopharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Grifols, 13.04% 17.96% 6.32%
Epirus Biopharmaceuticals -2,025.65% -208.66% -97.67%

Volatility & Risk

Grifols, has a beta of 0.98, suggesting that its stock price is 2% less volatile than the S&P 500. Comparatively, Epirus Biopharmaceuticals has a beta of 2.52, suggesting that its stock price is 152% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and target prices for Grifols, and Epirus Biopharmaceuticals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Grifols, 1 1 2 0 2.25
Epirus Biopharmaceuticals 0 0 0 0 N/A

Dividends

Grifols, pays an annual dividend of $0.28 per share and has a dividend yield of 1.3%. Epirus Biopharmaceuticals does not pay a dividend. Grifols, pays out 31.1% of its earnings in the form of a dividend.

Summary

Grifols, beats Epirus Biopharmaceuticals on 8 of the 10 factors compared between the two stocks.

Grifols, Company Profile

Grifols, S.A., a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company specializes in providing infusion solutions, nutrition products, and medical devices for use in hospitals and clinics. It operates through four segments: Bioscience, Diagnostic, Hospital, and Raw Materials and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use, including the reception, analysis, quarantine, classification, fractionation, and purification of plasma; and sells and distributes end products. This segment offers plasma products, such as IVIG, Factor VIII, A1PI, and albumin; and intramuscular immunoglobulins, ATIII, Factor IX, and plasma thromboplastin components. The Diagnostic segment focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products comprising analytical instruments, reagents, software, and related products for use in clinical and blood bank laboratories. This segment serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital segment manufactures and installs products used by hospitals consisting of parenteral solutions, and enteral and parenteral nutritional fluids. The Raw Materials and Others segment sells intermediate biological products; and renders manufacturing services to third party companies. The company also offers engineering services. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves hospitals and clinics, group purchasing organizations, governments, and other distributors through sales representatives, marketing partners, and third-party distributors. Grifols, S.A. was founded in 1940 and is headquartered in Barcelona, Spain.

Epirus Biopharmaceuticals Company Profile

EPIRUS Biopharmaceuticals, Inc. (Epirus) is a biopharmaceutical company. The Company focuses on biosimilars, which are biologic drugs. Its segment is the development and commercialization of biosimilar monoclonal antibodies for emerging markets. The Company’s products include BOW015, a biosimilar version of Remicade, which is a monoclonal antibody against tumor necrosis factor alpha (TNF-a); BOW050, a biosimilar version of Humira, which is an inhibitor of TNF-a used to treat inflammatory diseases; BOW070, a biosimilar version of Actemra, which is an immunosuppressive drug for the treatment of rheumatoid arthritis, polyarticular arthritis and systemic juvenile idiopathic arthritis; BOW090, a biosimilar version of STELARA, which is an immunosuppressant drug for the treatment of plaque psoriasis and psoriatic arthritis; BOW100, a biosimilar version of SIMPONI, which is an inhibitor of TNF-a, and BOW080, a biosimilar version of Soliris, which is used to treat ultra-rare blood disorders.

Receive News & Ratings for Grifols S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols S.A. and related companies with MarketBeat.com's FREE daily email newsletter.